Arcus Biosciences, Inc. (RCUS)

Price$22.74

Favorite Metrics

Price vs S&P 500 (26W)57.35%

Price vs S&P 500 (4W)2.57%

Market Capitalization$2.85B

All Metrics

Book Value / Share (Quarterly)$5.04

P/TBV (Annual)1.60x

Revenue Growth (3Y)30.16%

Cash Flow / Share (Quarterly)$-3.86

Price vs S&P 500 (YTD)-2.38%

Net Profit Margin (TTM)-110.05%

EPS (TTM)$-3.30

10-Day Avg Trading Volume0.74M

EPS Excl Extra (TTM)$-3.30

Revenue Growth (5Y)26.09%

EPS (Annual)$-3.29

ROI (Annual)-48.36%

Net Profit Margin (5Y Avg)-147.92%

Cash / Share (Quarterly)$7.83

Revenue Growth QoQ (YoY)26.92%

ROA (Last FY)-30.99%

Revenue Growth TTM (YoY)-15.12%

EBITD / Share (TTM)$-3.51

ROE (5Y Avg)-43.02%

Operating Margin (TTM)-120.55%

Cash Flow / Share (Annual)$-3.86

P/B Ratio4.52x

P/B Ratio (Quarterly)4.67x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)12.45x

ROA (TTM)-32.50%

EV / EBITDA (TTM)34.22x

EPS Incl Extra (Annual)$-3.29

Current Ratio (Annual)4.36x

Quick Ratio (Quarterly)4.32x

3-Month Avg Trading Volume1.37M

52-Week Price Return208.92%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$6.95

P/S Ratio (Annual)11.54x

Asset Turnover (Annual)0.22x

52-Week High$26.40

Operating Margin (5Y Avg)-162.13%

EPS Excl Extra (Annual)$-3.29

CapEx CAGR (5Y)-8.39%

Tangible BV CAGR (5Y)33.69%

26-Week Price Return66.10%

Quick Ratio (Annual)4.32x

13-Week Price Return-1.26%

Total Debt / Equity (Annual)0.16x

Current Ratio (Quarterly)4.36x

Enterprise Value$2,727.447

Revenue / Share Growth (5Y)10.21%

Asset Turnover (TTM)0.21x

Book Value / Share Growth (5Y)-8.18%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-142.91%

Cash / Share (Annual)$7.83

3-Month Return Std Dev69.46%

Net Income / Employee (TTM)$-1

ROE (Last FY)-55.94%

EPS Basic Excl Extra (Annual)$-3.29

P/FCF (TTM)114.02x

Receivables Turnover (TTM)10.68x

Total Debt / Equity (Quarterly)0.16x

EPS Incl Extra (TTM)$-3.30

Receivables Turnover (Annual)12.05x

ROI (TTM)-56.73%

P/S Ratio (TTM)13.02x

Pretax Margin (5Y Avg)-146.54%

Revenue / Share (Annual)$2.30

Tangible BV / Share (Annual)$9.01

Price vs S&P 500 (52W)173.82%

Year-to-Date Return1.76%

5-Day Price Return8.31%

EPS Normalized (Annual)$-3.29

ROA (5Y Avg)-20.03%

Net Profit Margin (Annual)-142.91%

Month-to-Date Return12.27%

Cash Flow / Share (TTM)$-3.91

EBITD / Share (Annual)$-3.50

Operating Margin (Annual)-156.28%

LT Debt / Equity (Annual)0.16x

ROI (5Y Avg)-40.46%

LT Debt / Equity (Quarterly)0.16x

EPS Basic Excl Extra (TTM)$-3.30

P/TBV (Quarterly)2.02x

P/B Ratio (Annual)4.67x

Pretax Margin (TTM)-110.05%

Book Value / Share (Annual)$5.04

Price vs S&P 500 (13W)-4.13%

Beta0.83x

P/FCF (Annual)6.60x

Revenue / Share (TTM)$1.85

ROE (TTM)-65.77%

52-Week Low$7.06

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.11

4.06

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
RCUSArcus Biosciences, Inc.	13.02x	-15.12%	—	—	$22.74
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Arcus Biosciences is a late clinical-stage biopharmaceutical company developing differentiated molecular therapies for cancer and inflammatory and autoimmune diseases. The company's pipeline includes several investigational drug candidates designed to address unmet medical needs in these therapeutic areas.